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Summary
Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes 
of cancer death in the Western world. The majority of colorectal cancers arise in sporadic form. 
The disease arises from the accumulation of mutations in oncogenes, tumor suppressor genes 
and mismatch repair genes during progression from normal colon epithelium to adenoma and 
metastatic carcinoma. Colorectal Cancer Subtyping Consortium describes four consensus mo-
lecular subtypes (CMS) of CRC: CMS1 (14%, microsatellite instability, immune, strong immune 
activation), CMS2 (37%, canonical, WNT and MYC signaling activation), CMS3 (13%, metabolic, 
epithelial and metabolic dysregulation) and CMS4 (23%, mesenchymal, transforming growth 
factor-β activation), while 13% of colorectal cancers remained mixed or “unclassified”.
This mini review will give some information about the most frequent molecular genetics 
changes in colorectal cancer and its molecular classification in four CMS subtypes due to its 
morphology, gene expression profile, somatic mutations and microsatellite instability.
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Colorectal cancer (CRC) is one of the most common cancers and represents 
the third most diagnosed cancer in men and the second most common cancer in 
women. Despite advances in surgery, chemotherapy and screening it is still one 
of the leading causes of cancer related death in the Western world [1].
Of all human cancers, the molecular genetic alterations in colorectal cancer 
are best understood. The disease arises from the accumulation of mutations in 
oncogenes, tumor suppressor genes and mismatch repair (MMR) genes during 
progression from normal colorectal epithelium to adenoma and metastatic car-
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local colorectal environment, individuals’s genetic profile as well as by heredi-
tary germline mutations [3,4].
The majority of colorectal cancers (75-80%) are sporadic, while around 20-
25% of CRC have a hereditary component. However, only 5% of CRC arise due 
to high risk hereditary syndromes, such as Lynch Syndrome (LS) (3-5%) and 
familial adenomatous polyposis (1%) while the remaining CRCs have a posi-
tive family history but cannot be categorized to any hereditary CRC syndrome. 
These familial CRC are caused by single nucleotide polymorphisms (SNP) in 
less penetrant genes such as cytokines. Many susceptibility loci have been iden-
tified, however, their value in CRC risk prediction remains low [5-7].
Colorectal cancer is not a homogenous disease and can be classified in differ-
ent subtypes which are characterized by specific molecular and morphological 
alterations. A major feature of colorectal cancer is genetic instability that can 
arise by at least two different mechanisms. According to The Cancer Genome 
Atlas (TCGA) the most CRC (around 84% of sporadic CRC) is characterized by 
chromosomal instability (CIN), with changes in chromosome number and struc-
ture including large deletions, gains, translocations and other chromosomal re-
arrangements. These molecular changes are described as a high frequency of 
DNA somatic copy number alterations (SCNA) and represent a hallmark of most 
tumors that arise by adenoma-carcinoma sequence [3,5,8-11]. Molecular genetic 
studies have associated CIN with activation of oncogenes (KRAS, PIK3CA) and 
inactivation of tumor suppressor genes (APC, SMAD4 and TP53) which go along 
with adenoma carcinoma sequence as it was first described by Fearon and Vo-
gelstein in 1990 [7]. The second group (13-16% of sporadic CRC) is hypermutated 
tumors. The etiology of hypermutated tumors is largely driven by the presence 
of microsatellite instability (MSI) due to defective DNA mismatch repair (MMR), 
specifically somatic hypermethylation of hMLH1 gene, one of the MMR genes 
as well as BRAF gene mutations [3,12-16]. The ultramutated colorectal cancers 
(3% of sporadic CRC) have an extremely high mutation rate due to the presence 
of a mutation that inactivates the proofreading function within the exonuclease 
domain of the DNA replicating enzyme POLE (encoding DNA polymerase e), or 
rarely of POLD1 (encoding DNA polymerase d1). Ultramutated tumors are mi-
crosatellite stable and do not exhibit loss of expression of MMR proteins [12,17].
Early attempts at gene expression profiling in order to stratify colorectal 
cancer were made by several groups, but showed little agreement with each 
other, suggesting different number of categories, and did not lead to a useful 
classification system [18,19]. Subsequently, an international expert consortium 
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(Colorectal Cancer Subtyping Consortium, CCSC) reached an agreement that 
describes four consensus molecular subtypes (CMS) after analysis of 18 differ-
ent CRC gene expression datasets of more than 4000 samples. Approximately 
87% of the 4151 samples that were analyzed by six expert groups were subclas-
sified in 4 consensus molecular subtypes (CMS) while 13% of colorectal cancers 
remained mixed or “unclassified”. These samples with mixed features possibly 
represent either a transition phenotype or intratumoral heterogeneity. Addition-
al molecular data, including mutations, SCNAs, promoter methylation status, 
and post-translational gene regulation, as well as biological characteristics were 
correlated with the subtypes [18,20,21], (Table 1).
Table 1. Consensus molecular subtypes of colorectal cancer [20,21]
CMS1 CMS2 CMS2 CMS4
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CMS1 (MSI-immune, 14 %) CRC are hypermutated due to defective DNA mi-
smatch repair with microsatellite instability (MSI) and MLH1 expression silen-
cing, high methylation (CpG island methylator phenotype, CIMP-high), frequent 
BRAF mutations and low SCNAs. This molecular subtype is in accordance with 
the previously well-characterized sporadic MSI CRC subgroup. Gene expressi-
on profiling revealed evidence of strong immune activation (immune respon-
se, PD1 activation, NK cell, Th1 cell and cytotoxic T cell infiltration) in CMS1, 
consistent with pathological descriptions of prominent tumor-infiltrating CD8+ 
cytotoxic T lymphocytes [18]. Patients with early stage MSI (CMS1) tumors have 
a better prognosis compared to patients with microsatellite stable (MSS) tumors. 
CMS1 have a good prognosis when detected before disease dissemination, in 
part, due to the presence of specific T-cell populations and natural killer cells. 
However, patients with the CMS1 tumors, which are more prevalent in the right 
colon, had a very poor survival rate after relapse [21].
The majority of colorectal cancers previously described as chromosomal in-
stability (CIN) are split in three subgroups based on transcriptomic profiling, but 
all three groups of tumors were characterized by high levels of SCNAs [18,22].
Colorectal cancer in the CMS2 (canonical, 37%) subgroup arises from the 
canonical adenoma-to-carcinoma sequence including APC, KRAS and p53 gene 
mutations [7]. CMS2 CRC predominantly displayed a differentiated epithelial 
cell phenotype with prominent WNT-β catenin and MYC signaling activation. 
CMS2 cancers are more commonly left sided lesions (59%) and with highest fi-
ve-year overall survival for all stages compared with colorectal cancers of other 
CMS subtypes [21].
The CMS3 (metabolic, 13%) subtype have fewer SCNAs and contain more 
MSI/hypermutated tumors than CMS2 and CMS4. Although KRAS mutations 
are present in all molecular subtypes, they are more prevalent in CMS3 CRC 
(in 68%). Gene expression analysis of CMS3 found predominantly epithelial 
signatures and evidence of metabolic dysregulation in a metabolic pathways, 
including glutamine, fatty acid, and lysophospholipid metabolism [18,20,21]. For 
metastic colorectal cancer, the higher frequency of KRAS mutations in CMS3 
tumors is an indicator of poor response to epidermal growth factor receptor 
(EGFR) monoclonal antibodies. In those tumors that are not positive to KRAS, 
BRAF or PIK3CA mutations, anti EGFR monoclonal antibodies may be useful 
[3,21]. Since the reprogramming of cellular metabolism is an established hall-
mark of cancer, preclinical studies have shown efficacy using inhibitors that tar-
get many metabolic processes, such as glucose transporters, glycolytic enzymes 
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and fatty acid synthase. These inhibitors may prove to be a useful treatment in 
KRAS mutant CRC [22-24].
CMS4 tumors (mesenchymal, 23%) show increased expression of epithelial 
to mesenchymal transition (EMT) genes and evidence of prominent transfor-
ming growth factor-β activation, with expression of genes involved in comple-
ment-associated inflammation, matrix remodeling, stromal invasion and angio-
genesis. CMS4 tumors exhibit very low levels of hypermutation, MSS status, and 
very high SCNA level. CRC of CMS4 subtype display a mesenchymal phenotype 
and an inflammatory microenvironment with prominent innate immune cells 
[20]. The level and nature of inflammation in primary CRC may be complex, but 
the type, density and intratumor location of immune cells can predict patient 
survival, often better than classical staging [25]. In the contrast to the anti-tumor 
immune environment of CMS1 cancers, the CMS4 tumor microenvironment is 
proinflammatory, with the presence of Treg cells, T helper 17 cells, myeloid-de-
rived suppressor cells, and tumor promoting macrophages. Patients with the 
CMS4 subtype, often diagnosed at advanced stages, had worse overall survival 
and worse relapse-free survival than patients in other CMS groups [18,21,22].
CMS classification system has been suggested by authors (Colorectal Can-
cer Subtyping Consortium) to be the most robust classification system currently 
available for CRC based on biological processes related to gene expression profi-
les and is suggested as a basis for clinical stratification in trials and other studies 
with potential for subtype-based targeted therapy [20,22].
Modern molecular platforms give the ability to characterize tumors at mul-
tiple levels and to define molecular and biological subtypes of cancer. Cancers 
could be divided into subtypes that are more or less aggressive. Identification of 
a more aggressive subtype may influence the type of their treatment. Molecular 
stratification and subclassification of tumors will add a step to traditional clini-
cal practice and better diagnosis and therapy of different types of cancer as well 
as colorectal cancer [26].
Integration of wide-ranging molecular data has generated two systems of 
classification of colorectal cancers: TCGA classification [12] and CMS classifi-
cation [20,22]. Both classifications have been proposed to allow better progno-
stication and are potentially important for future use in clinical trials and for 
multidisciplinary team discussions in oncology. All these results, and both cla-
ssification systems are a welcome step toward translating research findings to 
the clinicians but many more steps including optimization of molecular genetic 
testing are needed for clinical application.
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Sažetak
Molekularni podtipovi kolorektalnog karcinoma – kratki pregled
Kolorektalni karcinom je jedan od najčešćih zloćudnih tumora i jedan od vodećih uzroka 
smrti od raka u zemljama razvijenog svijeta, a najčešće se javlja u sporadičnom obliku. Ovaj 
zloćudni tumor nastaje kroz duži niz godina tijekom kojih kao posljedica mutacija u onkogeni-
ma, tumor supresorskim genima i genima za popravak DNA iz normalne sluznice kolona preko 
adenoma nastaje zloćudni metastatski karcinom. Nova CMS (od engl. Consensus Molecular Sub-
types) klasifikacija dijeli karcinome kolorektuma na četiri CMS podtipa: CMS1 (14%, pozitivni 
na mikrosatelitnu nestabilnost, jaka imunološka infiltracija tumora), CMS2 (37%, epitelni koji 
slijede adenom-karcinom slijed, aktivacija Wnt te Myc signalnog puta), CMS3 (13%, metabolički, 
epitelni s metaboličkom disregulacijom) te CMS4 (23%, mezenhimalni, jaka imunološka infil-
tracija strome, aktivacija TGF-β signalnog puta) dok 13% tumora ostaje neklasificirano odnosno 
miješanog podtipa.
U ovom kratkom preglednom radu opisane su molekularno genetičke promjene u karcino-
mima kolorektuma te molekularna klasifikacija ovog zloćudnog tumora na molekularne (CMS) 
podtipove s obzirom na morfologiju, transkriptomski profil, stečene mutacije i mikrosatelitnu 
nestabilnost.
Ključne riječi: karcinom kolorektuma; CMS klasifikacija; CMS molekularni podtipovi.
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